Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors
Abstract Successful therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have harnessed the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Evidence that SARS-CoV-2 exists as locally evolving variants suggests that immunological differences may impact the effectiveness of antibody-based treatments such as convalescent plasma and vaccines. Considering that near-sourced convalescent plasma is likely to reflect the antigenic composition of local viral strains, we hypothesized that convalescent plasma has a higher efficacy, as defined by death within 30 days of transfusion, when the convalescent plasma donor and treated patient were in close geographic proximity. Results of a series of modeling techniques applied to a national registry of hospitalized COVID-19 patients supported this hypothesis. These findings have implications for the interpretation of clinical studies, the ability to develop effective COVID-19 treatments, and, potentially, for the effectiveness of COVID-19 vaccines as additional locally-evolving variants continue to emerge..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2021.03.19.21253975 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI020200749 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI020200749 | ||
| 003 | DE-627 | ||
| 005 | 20240425104454.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210324s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.03.19.21253975 |2 doi | |
| 035 | |a (DE-627)XBI020200749 | ||
| 035 | |a (biorXiv)10.1101/2021.03.19.21253975 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kunze, Katie L. |e verfasserin |0 (orcid)0000-0001-6850-6823 |4 aut | |
| 245 | 1 | 0 | |a Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Successful therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have harnessed the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Evidence that SARS-CoV-2 exists as locally evolving variants suggests that immunological differences may impact the effectiveness of antibody-based treatments such as convalescent plasma and vaccines. Considering that near-sourced convalescent plasma is likely to reflect the antigenic composition of local viral strains, we hypothesized that convalescent plasma has a higher efficacy, as defined by death within 30 days of transfusion, when the convalescent plasma donor and treated patient were in close geographic proximity. Results of a series of modeling techniques applied to a national registry of hospitalized COVID-19 patients supported this hypothesis. These findings have implications for the interpretation of clinical studies, the ability to develop effective COVID-19 treatments, and, potentially, for the effectiveness of COVID-19 vaccines as additional locally-evolving variants continue to emerge. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Johnson, Patrick W. |e verfasserin |0 (orcid)0000-0001-8365-1375 |4 aut | |
| 700 | 1 | |a van Helmond, Noud |e verfasserin |0 (orcid)0000-0003-1395-4754 |4 aut | |
| 700 | 1 | |a Senefeld, Jonathon W. |e verfasserin |0 (orcid)0000-0001-8116-3538 |4 aut | |
| 700 | 1 | |a Petersen, Molly M. |e verfasserin |0 (orcid)0000-0002-7779-4940 |4 aut | |
| 700 | 1 | |a Klassen, Stephen A. |e verfasserin |0 (orcid)0000-0002-4560-8728 |4 aut | |
| 700 | 1 | |a Wiggins, Chad C. |e verfasserin |0 (orcid)0000-0002-6458-0142 |4 aut | |
| 700 | 1 | |a Klompas, Allan M. |e verfasserin |0 (orcid)0000-0001-8852-4666 |4 aut | |
| 700 | 1 | |a Bruno, Katelyn A. |e verfasserin |0 (orcid)0000-0001-8980-6059 |4 aut | |
| 700 | 1 | |a Mills, John R. |e verfasserin |0 (orcid)0000-0003-1025-4760 |4 aut | |
| 700 | 1 | |a Theel, Elitza S. |e verfasserin |0 (orcid)0000-0002-6886-2294 |4 aut | |
| 700 | 1 | |a Buras, Matthew R. |e verfasserin |0 (orcid)0000-0001-6503-0989 |4 aut | |
| 700 | 1 | |a Golafshar, Michael A. |e verfasserin |0 (orcid)0000-0001-7666-7782 |4 aut | |
| 700 | 1 | |a Sexton, Matthew A. |e verfasserin |0 (orcid)0000-0002-6825-7297 |4 aut | |
| 700 | 1 | |a Soto, Juan C. Diaz |e verfasserin |0 (orcid)0000-0001-9173-1308 |4 aut | |
| 700 | 1 | |a Baker, Sarah E. |e verfasserin |0 (orcid)0000-0001-9647-7660 |4 aut | |
| 700 | 1 | |a Shepherd, John R.A. |e verfasserin |0 (orcid)0000-0001-5022-326X |4 aut | |
| 700 | 1 | |a Verdun, Nicole C. |e verfasserin |4 aut | |
| 700 | 1 | |a Marks, Peter |e verfasserin |0 (orcid)0000-0001-5619-4404 |4 aut | |
| 700 | 1 | |a Paneth, Nigel S. |e verfasserin |0 (orcid)0000-0002-0151-966X |4 aut | |
| 700 | 1 | |a Fairweather, DeLisa |e verfasserin |0 (orcid)0000-0003-3093-1810 |4 aut | |
| 700 | 1 | |a Wright, R. Scott |e verfasserin |0 (orcid)0000-0002-0625-0444 |4 aut | |
| 700 | 1 | |a Casadevall, Arturo |e verfasserin |0 (orcid)0000-0002-9402-9167 |4 aut | |
| 700 | 1 | |a Carter, Rickey E. |e verfasserin |0 (orcid)0000-0002-0818-273X |4 aut | |
| 700 | 1 | |a Joyner, Michael J. |e verfasserin |0 (orcid)0000-0002-7135-7643 |4 aut | |
| 700 | 1 | |a van Buskirk, Camille M. |e verfasserin |4 aut | |
| 700 | 1 | |a Winters, Jeffrey L. |e verfasserin |0 (orcid)0000-0001-8654-3732 |4 aut | |
| 700 | 1 | |a Stubbs, James R. |e verfasserin |0 (orcid)0000-0002-3270-4913 |4 aut | |
| 700 | 1 | |a Senese, Katherine A. |e verfasserin |0 (orcid)0000-0002-9413-5664 |4 aut | |
| 700 | 1 | |a Pletsch, Michaela C. |e verfasserin |4 aut | |
| 700 | 1 | |a Buchholtz, Zachary A. |e verfasserin |4 aut | |
| 700 | 1 | |a Rea, Robert F. |e verfasserin |4 aut | |
| 700 | 1 | |a Herasevich, Vitaly |e verfasserin |0 (orcid)0000-0002-0214-0651 |4 aut | |
| 700 | 1 | |a Whelan, Emily R. |e verfasserin |0 (orcid)0000-0002-0410-0549 |4 aut | |
| 700 | 1 | |a Clayburn, Andrew J. |e verfasserin |0 (orcid)0000-0001-8729-1805 |4 aut | |
| 700 | 1 | |a Larson, Kathryn F. |e verfasserin |0 (orcid)0000-0003-2565-3318 |4 aut | |
| 700 | 1 | |a Ripoll, Juan G. |e verfasserin |0 (orcid)0000-0003-4908-9774 |4 aut | |
| 700 | 1 | |a Andersen, Kylie J. |e verfasserin |0 (orcid)0000-0001-8668-2871 |4 aut | |
| 700 | 1 | |a Lesser, Elizabeth R. |e verfasserin |0 (orcid)0000-0001-9414-7107 |4 aut | |
| 700 | 1 | |a Vogt, Matthew N.P. |e verfasserin |0 (orcid)0000-0003-0721-8451 |4 aut | |
| 700 | 1 | |a Dennis, Joshua J. |e verfasserin |0 (orcid)0000-0002-1135-9006 |4 aut | |
| 700 | 1 | |a Regimbal, Riley J. |e verfasserin |0 (orcid)0000-0002-0195-5875 |4 aut | |
| 700 | 1 | |a Bauer, Philippe R. |e verfasserin |0 (orcid)0000-0001-8429-3581 |4 aut | |
| 700 | 1 | |a Blair, Janis E. |e verfasserin |0 (orcid)0000-0003-2267-1473 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41467-021-25113-5 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.03.19.21253975 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||